ProPhase Labs, Inc. Accumulated Other Comprehensive Income
ProPhase Labs, Inc. (PRPH) had Accumulated Other Comprehensive Income of -$198.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-19
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$198.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$198.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$198.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$198.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$198.00K 10-Q · filed 2026-08-19 |
| 2026-03-31 | -$198.00K 10-Q/A · filed 2026-07-09 |
| 2025-12-31 | -$198.00K 10-Q · filed 2026-08-19 |
| 2025-09-30 | -$198.00K 10-Q · filed 2025-11-19 |
| 2025-06-30 | -$196.00K 10-Q · filed 2025-08-13 |
| 2025-03-31 | -$198.00K 10-Q · filed 2025-05-20 |
| 2024-12-31 | -$198.00K 10-K · filed 2026-06-01 |
| 2024-09-30 | -$197.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | -$198.00K 10-Q · filed 2024-08-14 |
| 2024-03-31 | -$140.00K 10-Q · filed 2024-05-10 |
| 2023-12-31 | -$300.00K 10-K · filed 2025-04-01 |
| 2023-09-30 | -$1.44M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $588.00K 10-Q · filed 2023-08-11 |
| 2023-03-31 | $92.00K 10-Q · filed 2023-05-12 |
| 2022-12-31 | $757.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | -$287.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$236.00K 10-Q · filed 2022-08-12 |
| 2022-03-31 | -$138.00K 10-Q · filed 2022-05-13 |
| 2021-12-31 | -$175.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | -$122.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$89.00K 10-Q · filed 2021-08-13 |
| 2021-03-31 | -$22.00K 10-Q · filed 2021-05-14 |
| 2020-12-31 | -$11.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | -$4.00K 10-Q · filed 2020-11-19 |
| 2020-06-30 | $4.00K 10-Q · filed 2020-08-11 |
| 2020-03-31 | $9.00K 10-Q · filed 2020-05-12 |
| 2019-12-31 | -$2.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | -$6.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | -$1.00K 10-Q · filed 2019-08-12 |
| 2019-03-31 | -$9.00K 10-Q · filed 2019-05-14 |
| 2018-12-31 | -$24.00K 10-K · filed 2020-03-26 |
| 2018-09-30 | -$24.00K 10-Q · filed 2018-11-14 |
| 2018-06-30 | -$53.00K 10-Q · filed 2018-08-20 |
| 2018-03-31 | -$121.00K 10-Q/A · filed 2018-08-20 |
| 2017-12-31 | -$78.00K 10-K · filed 2019-03-26 |
| 2017-09-30 | -$35.00K 10-Q/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |